– USA, MA – Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the appointment of Joshua Reed to its Board of Directors as an independent director.
Mr. Reed is a highly accomplished leader in the biopharmaceutical industry with over two decades of experience in financial operations, strategic planning, and investment banking. He will serve as chair of the audit committee on Scholar Rock’s Board.
“We are delighted to build upon the breadth of expertise by welcoming Joshua to Scholar Rock’s Board of Directors,” said Board Chairman, David Hallal. “Scholar Rock is at an important juncture in its evolution and Joshua brings an essential operational and strategic perspective from clinical and commercial stage companies that will be invaluable to the company’s next phase of growth.”
About Joshua Reed
Mr. Reed joined Aldeyra Therapeutics as CFO in 2018 and is responsible for the finance, compliance, information technology, human resources, and facilities functions. Before Aldeyra, he held roles of increasing responsibility at Bristol-Myers Squibb, including supply chain finance, operations finance, financial planning and analysis, mergers and acquisitions, and most recently as the VP and Head of Finance for the United States and Puerto Rico Operations. Before joining BMS, Mr. Reed served as VP, Strategic Business Development at JPMorgan Chase and worked in investment banking at Credit Suisse First Boston.
“I am thrilled to be joining the Scholar Rock Board and working alongside the team to build and advance the company through several potentially transformative milestones,” said Mr. Reed. “Scholar Rock is on the path to revolutionizing the treatment paradigm for patients affected by a wide range of serious diseases, including spinal muscular atrophy and cancer, and I am excited to be part of this journey towards achieving their goal of meaningfully improving the lives of patients.”
Mr. Reed received a B.S. in Finance from Rutgers University and an MBA from the University of Michigan’s Ross School of Business.
About Scholar Rock
Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Scholar Rock is creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, fibrosis, and anemia. Scholar Rock’s approach to targeting the molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level. By developing product candidates that act in the disease microenvironment, the Company intends to avoid the historical challenges associated with inhibiting growth factors for therapeutic effect. Scholar Rock believes its focus on biologically validated growth factors may facilitate a more efficient development path.
For more information: https://scholarrock.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.